Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01959425
Other study ID # OAT-149
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date April 17, 2013
Est. completion date October 7, 2019

Study information

Verified date November 2020
Source Biosense Webster, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.


Description:

Patients undergoing successful cardiac ablation for atrial fibrillation who remain AF recurrence-free 3 months after successful ablation and continue to meet the inclusion/exclusion criteria will be screened for enrollment in the trial. After fulfilling all of the inclusion/exclusion criteria, patients who consent to participate in the study and remain AF recurrence-free will be randomized to one of two study arms: (1) OAT Withdrawal (Test) Group or (2) OAT (Control) Group and participate in the Evaluation Period (12 months).


Recruitment information / eligibility

Status Terminated
Enrollment 80
Est. completion date October 7, 2019
Est. primary completion date October 7, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Successful cardiac ablation for AF 2. Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation (AF recurrence during 3-month blanking period is excluded). 3. Patient must have been on a commercially approved anticoagulation therapy for at least two (2) months prior to randomization in the OAT Study. 4. CHADS2 score = 2 or CHA2DS2-VASc score (=3) 5. Left ventricular ejection fraction > 25% 6. LA size < 65 7. High risk for thromboembolic events (i.e., CHADS2 score = 2 or CHA2DS2-VASc score = 3) and require OAT before undergoing cardiac ablation 8. Able and willing to comply with all pre- and follow-up testing and requirements 9. Signed informed consent form 10. Age 18 years or older Exclusion Criteria: 1. OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up). 2. Any cardiac surgery within the past 60 days (2 months) or valvular cardiac surgical procedure at any time (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve) 3. Previous myocardial infarction (MI) or a percutaneous coronary intervention PCI within the past 3 months 4. Awaiting cardiac transplantation or other cardiac surgery within the next 365 days (12 months) 5. Documented left atrial thrombus 6. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or COPD) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms 7. Significant medical problem that in the opinion of the investigator would preclude enrollment in this study 8. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal) 9. Acute illness or active systemic infection or sepsis 10. Unstable angina 11. Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially available anticoagulation medication) 12. History of blood clotting or bleeding abnormalities 13. Life expectancy less than 360 days (12 months) 14. Uncontrolled Heart Failure or NYHA Class III or IV heart failure 15. Enrollment in a clinical study evaluating another device or drug, within the past 6 months 16. Unable or unwilling to comply with protocol requirements

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Off OAT Group (Test)
Discontinuation of OAT Therapy
On OAT Group (Control)
Continuation of OAT Therapy

Locations

Country Name City State
France Le Centre Hospitalier de Bordeaux Bordeaux Pessac
Germany Asklepios Klinik St. Georg Hamburg
Italy Ospedale dell'Angelo Mestre Venezia
United States Texas Cardiac Arrhythmia Research Foundation Austin Texas
United States MetroHealth Medical Center Cleveland Ohio
United States University of Kansas Hospitals Kansas City Kansas
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Biosense Webster, Inc.

Countries where clinical trial is conducted

United States,  France,  Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Occurrence of Any Major Thromboembolic Event Composite endpoint represented by the occurrence of any major thromboembolic event (stroke [i.e., ischemic, hemorrhagic or cryptogenic] that is an acute onset of a focal neurologic deficit of presumed vascular origin lasting for =24 hours or resulting in death) or major hemorrhagic complication (major bleeding) during the 12-month Evaluation Period. 12 months
Secondary Percentage of Participants With Minor Bleeds Any clinical bleed that does not meet criteria for a major hemorrhagic event during the 12-month Evaluation Period. 12 months
Secondary Percentage of Participants Hospitalized With Any Thromboembolic or Major Hemorrhagic Event Hospitalization due to any thromboembolic or major hemorrhagic event during the 12-month Evaluation Period. 12 months
Secondary Percentage of Expired Participants All cause mortality during the 12-month Evaluation Period. 12 months
Secondary Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Physical Component Summary (PCS) The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability. Baseline, 3 months, 12 months
Secondary Mean SF-36 Quality of Life Scores of Participants at Baseline, 3 Months, and 12 Months: Mental Component Summary (MCS) The 36-Item Short Form Health Survey (SF-36) is a validated health-related quality of life (HRQOL) tool used to measure the physical and mental health status of the study population. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score on the assumption that each question carries equal weight. Scores can be summed together to contribute to two summary scores, a physical component score and a mental component score. The lower the score, the more disability. Baseline, 3 months, 12 months
Secondary Percentage of Participants With Atrial Fibrillation Recurrence Recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects with recurrence of atrial fibrillation were immediately exited from the study. 12 months
Secondary Percentage of Participants With Repeat Ablation Repeat ablations performed due to recurrence of atrial fibrillation during the 12-month Evaluation Period. Subjects that required a repeat ablation were immediately exited from the study. 12 months
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4